Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.88 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.65 |
| ▸ | HTR3B | O95264 | 7/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR1F | P30939 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | HTR5A | P47898 | 1/20 | 0.65 |
| ▸ | HTR6 | P50406 | 1/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolasetron SCHEMBL678304 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL41146 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL41145 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL7328772 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL7328761 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5013150 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5655022 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL30167868 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1237588 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5013147 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981524-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| WO-2007092616-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060276404-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | HTR3A 2261/4885KCNH2 3777/4885SLC6A4 2567/4885 |
| US-20070274951-A1 | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto | PREP, CTRL, SERPINB1 | HTR3A 2584/4885KCNH2 4854/4885SLC6A4 3319/4885 |
| US-20060276404-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | HTR3A 2261/4885KCNH2 3777/4885SLC6A4 2567/4885 |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | HTR3A 2261/4885KCNH2 3777/4885SLC6A4 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.